Research ExplorerPublicationsUpdate Breast Cancer 2023 Part 2 - Advanced-Stage Breast Can...

Update Breast Cancer 2023 Part 2 - Advanced-Stage Breast Cancer

Standard

Update Breast Cancer 2023 Part 2 - Advanced-Stage Breast Cancer. / Lux, Michael P; Hartkopf, Andreas D; Fehm, Tanja N; Welslau, Manfred; Müller, Volkmar; Schütz, Florian; Fasching, Peter A; Janni, Wolfgang; Witzel, Isabell; Thomssen, Christoph; Beierlein, Milena; Belleville, Erik; Untch, Michael; Thill, Marc; Tesch, Hans; Ditsch, Nina; Aktas, Bahriye; Banys-Paluchowski, Maggie; Kolberg-Liedtke, Cornelia; Wöckel, Achim; Kolberg, Hans-Christian; Harbeck, Nadia; Bartsch, Rupert; Schneeweiss, Andreas; Ettl, Johannes; Würstlein, Rachel; Krug, David; Taran, Florin-Andrei; Lüftner, Diana; Stickeler, Elmar.

In: GEBURTSH FRAUENHEILK, Vol. 83, No. 6, 06.2023, p. 664-672.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Lux, MP, Hartkopf, AD, Fehm, TN, Welslau, M, Müller, V, Schütz, F, Fasching, PA, Janni, W, Witzel, I, Thomssen, C, Beierlein, M, Belleville, E, Untch, M, Thill, M, Tesch, H, Ditsch, N, Aktas, B, Banys-Paluchowski, M, Kolberg-Liedtke, C, Wöckel, A, Kolberg, H-C, Harbeck, N, Bartsch, R, Schneeweiss, A, Ettl, J, Würstlein, R, Krug, D, Taran, F-A, Lüftner, D & Stickeler, E 2023, 'Update Breast Cancer 2023 Part 2 - Advanced-Stage Breast Cancer', GEBURTSH FRAUENHEILK, vol. 83, no. 6, pp. 664-672. https://doi.org/10.1055/a-2074-0125

APA

Lux, M. P., Hartkopf, A. D., Fehm, T. N., Welslau, M., Müller, V., Schütz, F., Fasching, P. A., Janni, W., Witzel, I., Thomssen, C., Beierlein, M., Belleville, E., Untch, M., Thill, M., Tesch, H., Ditsch, N., Aktas, B., Banys-Paluchowski, M., Kolberg-Liedtke, C., ... Stickeler, E. (2023). Update Breast Cancer 2023 Part 2 - Advanced-Stage Breast Cancer. GEBURTSH FRAUENHEILK, 83(6), 664-672. https://doi.org/10.1055/a-2074-0125

Vancouver

Lux MP, Hartkopf AD, Fehm TN, Welslau M, Müller V, Schütz F et al. Update Breast Cancer 2023 Part 2 - Advanced-Stage Breast Cancer. GEBURTSH FRAUENHEILK. 2023 Jun;83(6):664-672. https://doi.org/10.1055/a-2074-0125

Bibtex

@article{af327b12b3ef4305b8fdc4bed4a8cd98,
title = "Update Breast Cancer 2023 Part 2 - Advanced-Stage Breast Cancer",
abstract = "In recent years, a number of new therapies have led to advances in the treatment of patients with advanced breast carcinoma. These substances are mainly CDK4/6 inhibitors and other substances that can overcome endocrine resistance, oral selective estrogen receptor degraders, antibody drug conjugates (ADCs), and PARP inhibitors. This review summarizes and evaluates the latest study results that have been published in recent months. This includes the overall survival data of the Destiny-Breast03 study, the first analysis of the CAPItello-291 study, the comparison of CDK4/6 inhibitor treatment with chemotherapy in the first line of therapy (RIGHT Choice study), the first analysis of the Destiny-Breast02 study in the treatment setting after T-DM1 treatment, and the first analysis of the Serena-2 study. Most of these studies have the potential to significantly change the therapeutic landscape for patients with advanced breast carcinoma and show that the continued rapid development of new therapies is always producing new results.",
author = "Lux, {Michael P} and Hartkopf, {Andreas D} and Fehm, {Tanja N} and Manfred Welslau and Volkmar M{\"u}ller and Florian Sch{\"u}tz and Fasching, {Peter A} and Wolfgang Janni and Isabell Witzel and Christoph Thomssen and Milena Beierlein and Erik Belleville and Michael Untch and Marc Thill and Hans Tesch and Nina Ditsch and Bahriye Aktas and Maggie Banys-Paluchowski and Cornelia Kolberg-Liedtke and Achim W{\"o}ckel and Hans-Christian Kolberg and Nadia Harbeck and Rupert Bartsch and Andreas Schneeweiss and Johannes Ettl and Rachel W{\"u}rstlein and David Krug and Florin-Andrei Taran and Diana L{\"u}ftner and Elmar Stickeler",
note = "The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).",
year = "2023",
month = jun,
doi = "10.1055/a-2074-0125",
language = "English",
volume = "83",
pages = "664--672",
journal = "GEBURTSH FRAUENHEILK",
issn = "0016-5751",
publisher = "Georg Thieme Verlag KG",
number = "6",

}

RIS

TY - JOUR

T1 - Update Breast Cancer 2023 Part 2 - Advanced-Stage Breast Cancer

AU - Lux, Michael P

AU - Hartkopf, Andreas D

AU - Fehm, Tanja N

AU - Welslau, Manfred

AU - Müller, Volkmar

AU - Schütz, Florian

AU - Fasching, Peter A

AU - Janni, Wolfgang

AU - Witzel, Isabell

AU - Thomssen, Christoph

AU - Beierlein, Milena

AU - Belleville, Erik

AU - Untch, Michael

AU - Thill, Marc

AU - Tesch, Hans

AU - Ditsch, Nina

AU - Aktas, Bahriye

AU - Banys-Paluchowski, Maggie

AU - Kolberg-Liedtke, Cornelia

AU - Wöckel, Achim

AU - Kolberg, Hans-Christian

AU - Harbeck, Nadia

AU - Bartsch, Rupert

AU - Schneeweiss, Andreas

AU - Ettl, Johannes

AU - Würstlein, Rachel

AU - Krug, David

AU - Taran, Florin-Andrei

AU - Lüftner, Diana

AU - Stickeler, Elmar

N1 - The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

PY - 2023/6

Y1 - 2023/6

N2 - In recent years, a number of new therapies have led to advances in the treatment of patients with advanced breast carcinoma. These substances are mainly CDK4/6 inhibitors and other substances that can overcome endocrine resistance, oral selective estrogen receptor degraders, antibody drug conjugates (ADCs), and PARP inhibitors. This review summarizes and evaluates the latest study results that have been published in recent months. This includes the overall survival data of the Destiny-Breast03 study, the first analysis of the CAPItello-291 study, the comparison of CDK4/6 inhibitor treatment with chemotherapy in the first line of therapy (RIGHT Choice study), the first analysis of the Destiny-Breast02 study in the treatment setting after T-DM1 treatment, and the first analysis of the Serena-2 study. Most of these studies have the potential to significantly change the therapeutic landscape for patients with advanced breast carcinoma and show that the continued rapid development of new therapies is always producing new results.

AB - In recent years, a number of new therapies have led to advances in the treatment of patients with advanced breast carcinoma. These substances are mainly CDK4/6 inhibitors and other substances that can overcome endocrine resistance, oral selective estrogen receptor degraders, antibody drug conjugates (ADCs), and PARP inhibitors. This review summarizes and evaluates the latest study results that have been published in recent months. This includes the overall survival data of the Destiny-Breast03 study, the first analysis of the CAPItello-291 study, the comparison of CDK4/6 inhibitor treatment with chemotherapy in the first line of therapy (RIGHT Choice study), the first analysis of the Destiny-Breast02 study in the treatment setting after T-DM1 treatment, and the first analysis of the Serena-2 study. Most of these studies have the potential to significantly change the therapeutic landscape for patients with advanced breast carcinoma and show that the continued rapid development of new therapies is always producing new results.

U2 - 10.1055/a-2074-0125

DO - 10.1055/a-2074-0125

M3 - SCORING: Journal article

C2 - 37916184

VL - 83

SP - 664

EP - 672

JO - GEBURTSH FRAUENHEILK

JF - GEBURTSH FRAUENHEILK

SN - 0016-5751

IS - 6

ER -